Illumina Company Profile (NASDAQ:ILMN)

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Tuesday, August, 1st. The company reported $0.82 EPS for the quarter, beating the Zacks' consensus estimate of $0.68 by $0.14. The business had revenue of $662 million for the quarter, compared to analysts' expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.86 earnings per share. View Illumina's Earnings History.

Illumina updated its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share guidance of $3.60-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.63. The company issued revenue guidance of +12% to ~$2.69 billion, compared to the consensus revenue estimate of $2.66 billion.

19 brokers have issued twelve-month price objectives for Illumina's stock. Their forecasts range from $122.00 to $250.00. On average, they anticipate Illumina's share price to reach $179.15 in the next twelve months. View Analyst Ratings for Illumina.

Here are some recent quotes from research analysts about Illumina stock:

• 1. Canaccord Genuity analysts commented, "Shipments to China grew +16% and we believe China is likely to be a double-digit grower for ILMN over the next several years, driven by the Chinese Precision Medicine Initiative," (8/7/2017)
• 2. According to Zacks Investment Research, "Illumina exited the second quarter on a solid note, with both earnings and revenues beating the Zacks Consensus Estimate. The top line was strong on new product launches including the VeriSeq NIPT Solution in Europe and the strength in NovaSeq. Outside the U.S., the rate of NIPT adoption is increasing. In this regard to note, over the last three months, Illumina was trading above the broader industry. The company’s raised guidance is encouraging indicating this bullish trend to continue in the coming period. We are currently looking forward to the performance of the Extended RAS Panel that is slated for launch in the third quarter. We are also looking forward to GRAIL, Illumina’s venture in the cancer screening market. On the flip side, weak margins owing to NovaSeq launch, higher array services revenues and product mix within sequencing consumables will continue to act as deterrents. Also, NIH funding issue and a tough competitive landscap" (8/4/2017)

Some companies that are related to Illumina include Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR) and Natus Medical Incorporated (BABY).

Illumina's management team includes the folowing people:

• Jay T. Flatley, Executive Chairman of the Board
• Francis A. deSouza, President, Chief Executive Officer, Director
• Sam Samad, Chief Financial Officer, Senior Vice President
• Marc A. Stapley, Executive Vice President, Chief Administrative Officer
• Garret Hampton Ph.D., Executive Vice President - Clinical Genomics
• Omead Ostadan, Executive Vice President - Operations, Products and Strategy
• Mostafa Ronaghi Ph.D., Chief Technology Officer, Senior Vice President
• Charles E. Dadswell, Senior Vice President, General Counsel, Secretary
• Mark Van Oene, Senior Vice President, Chief Commercial Officer
• Arthur Blaine Bowman, Lead Independent Director

Illumina's stock is owned by a number of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.80%), Capital Research Global Investors (8.91%), Vanguard Group Inc. (6.78%), Jennison Associates LLC (3.18%), Capital World Investors (1.46%) and TIAA CREF Investment Management LLC (1.01%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Christian O Henry, Daniel Bradbury, David R Walt, Frances Arnold, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Nicholas Naclerio, Oene Mark Van, Omead Ostadan, Paul L Bianchi, Robert S Epstein and Roy A Whitfield. View Institutional Ownership Trends for Illumina.

Illumina's stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Aviva PLC, Capital Research Global Investors, Jennison Associates LLC, FMR LLC, Baillie Gifford & Co., FIL Ltd and APG Asset Management N.V.. Company insiders that have sold Illumina stock in the last year include A Blaine Bowman, Charles Dadswell, Daniel Bradbury, Frances Arnold, Jay T Flatley, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van and Omead Ostadan. View Insider Buying and Selling for Illumina.

Illumina's stock was bought by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, HPM Partners LLC, Fred Alger Management Inc., TIAA CREF Investment Management LLC, Capital World Investors, American Century Companies Inc., Janus Henderson Group PLC and Renaissance Technologies LLC. View Insider Buying and Selling for Illumina.

Shares of Illumina can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Illumina stock can currently be purchased for approximately $200.24.